JP2015134824A5 - - Google Patents

Download PDF

Info

Publication number
JP2015134824A5
JP2015134824A5 JP2015090887A JP2015090887A JP2015134824A5 JP 2015134824 A5 JP2015134824 A5 JP 2015134824A5 JP 2015090887 A JP2015090887 A JP 2015090887A JP 2015090887 A JP2015090887 A JP 2015090887A JP 2015134824 A5 JP2015134824 A5 JP 2015134824A5
Authority
JP
Japan
Prior art keywords
compound
vitreous
cornea
pharmaceutically acceptable
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015090887A
Other languages
English (en)
Japanese (ja)
Other versions
JP6124943B2 (ja
JP2015134824A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015134824A publication Critical patent/JP2015134824A/ja
Publication of JP2015134824A5 publication Critical patent/JP2015134824A5/ja
Application granted granted Critical
Publication of JP6124943B2 publication Critical patent/JP6124943B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015090887A 2009-06-17 2015-04-27 Sap変異体及びその使用 Expired - Fee Related JP6124943B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26896109P 2009-06-17 2009-06-17
US61/268,961 2009-06-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012516311A Division JP5822826B2 (ja) 2009-06-17 2010-06-17 Sap変異体及びその使用

Publications (3)

Publication Number Publication Date
JP2015134824A JP2015134824A (ja) 2015-07-27
JP2015134824A5 true JP2015134824A5 (enExample) 2017-03-16
JP6124943B2 JP6124943B2 (ja) 2017-05-10

Family

ID=43354870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012516311A Expired - Fee Related JP5822826B2 (ja) 2009-06-17 2010-06-17 Sap変異体及びその使用
JP2015090887A Expired - Fee Related JP6124943B2 (ja) 2009-06-17 2015-04-27 Sap変異体及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012516311A Expired - Fee Related JP5822826B2 (ja) 2009-06-17 2010-06-17 Sap変異体及びその使用

Country Status (10)

Country Link
US (2) US8329659B2 (enExample)
EP (2) EP2987803B1 (enExample)
JP (2) JP5822826B2 (enExample)
AU (1) AU2010262847B2 (enExample)
CA (2) CA2765394C (enExample)
DK (2) DK2987803T3 (enExample)
ES (2) ES2552793T3 (enExample)
HU (2) HUE041034T2 (enExample)
PL (1) PL2987803T3 (enExample)
WO (1) WO2010148234A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
EP2790690A4 (en) * 2011-12-14 2015-08-12 Texas A & M Univ Sys COMPOSITIONS AND METHODS OF MANAGING NEUTROPHILIC MOVEMENTS USING THE SERUM AMYLOID P (SAP)
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
WO2016168612A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
CN108114001B (zh) * 2017-12-23 2023-05-30 中国科学院海洋研究所 一种诱导海产双壳贝类产卵的诱导剂及其应用方法
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections
BR112023008317A2 (pt) * 2020-11-02 2024-02-06 Attralus Inc Proteínas de fusão sap fc e métodos de uso

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023A (en) * 1847-03-20 Stocking-loom
GB1562244A (en) * 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5272258A (en) 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
WO1992021364A1 (en) 1991-05-31 1992-12-10 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US6054121A (en) * 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
US5804446A (en) * 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
AU7043694A (en) 1993-05-27 1994-12-20 Regents Of The University Of Michigan, The Method of treatment and prevention of immune complex-induced lung injury
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5981470A (en) 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
AU712819B2 (en) 1996-01-25 1999-11-18 Profylakse Aps Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CA2321136A1 (en) * 1998-02-17 1999-08-19 Medarex, Inc. Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
CN1235559C (zh) 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6600019B2 (en) * 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001074300A1 (en) 2000-03-30 2001-10-11 Brennen Medical, Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) * 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) * 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
JP4922560B2 (ja) * 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
EP1597281A1 (en) 2003-02-27 2005-11-23 TheraVision GmbH Method for reducing levels of c-reactive protein
EP1747237A4 (en) 2004-04-16 2008-05-21 Macrogenics Inc SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
US7378504B2 (en) 2004-06-03 2008-05-27 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)
WO2006002930A2 (en) 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
NZ553118A (en) 2004-09-02 2009-12-24 Genentech Inc Anti-FC-gamma RIIB receptor antibody and uses therefor
AU2005286763A1 (en) * 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
WO2009009034A2 (en) * 2007-07-06 2009-01-15 Promedior, Inc Methods and compositions useful in the treatment of mucositis
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk

Similar Documents

Publication Publication Date Title
JP2015509500A5 (enExample)
JP7022735B2 (ja) 持続的薬物送達インプラントによる眼の状態の治療の方法
JP2017517363A5 (enExample)
WO2010105130A3 (en) Opthalmic drug delivery system and applications
JP2008538215A5 (enExample)
Mateo et al. Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation
JP2014533274A5 (enExample)
PL369246A1 (en) Ophthalmic drug delivery device
Tomey et al. Aqueous misdirection and flat chamber after posterior chamber implants with and without trabeculectomy
Wu et al. Selective laser trabeculoplasty complicated by cystoid macular edema: report of two cases
JP2024506384A5 (enExample)
JP2013513606A5 (enExample)
Park et al. Spontaneous malignant glaucoma in a longstanding hypotonous eye
MD870Y (en) Method for treating senile cataract
RU2688960C1 (ru) Способ комбинированного хирургического лечения вторичной глаукомы, вызванной эмульгированием силикона
Takkar et al. Re: Bouheraoua et al.: Decreased Corneal Sensation and Subbasal Nerve Density, and Thinned Corneal Epithelium as a Result of 360‐Degree Laser Retinopexy
Hae-Won et al. Transscleral IOL Fixation With Preserved Anterior Vitreous Face in Marfan Syndrome With Ectopia Lentis
Peyman Intraocular haemorrhage: case report
Shilova et al. Novel maneuver for the alleviation of pseudophakic optic capture and consequent pupillary block: A case report and technique
Son et al. A case of malignant glaucoma in a vitrectomized eye
Nowroozzadeh Prostaglandin analogs may aggravate myopic regression after laser in situ keratomileusis
Erdurmuş et al. Circumferential Pupillary Capture by IOL due to In-traocular Gas Tamponade: A Case Report
Hwang et al. The effect of posterior subtenon triamcinolone injection in panretinal photocoagulation induced visual dysfunction of diabetic retinopathy
Lee Elevated intraocular pressure: case report
Ha et al. Two Cases of Acute Chorioretinal Atrophy after Traumatic Cataract Extraction and Intraocular Lens Scleral Fixation